Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Frequency of EGFR Mutations in Non-small Cell Lung Cancer Patients: Screening Data from West Siberia

  • Gervas, Polina (Federal State Budgetary Scientific Institution "Tomsk Cancer Research Institute") ;
  • Ivanova, Anna (Federal State Budgetary Scientific Institution "Tomsk Cancer Research Institute") ;
  • Vasiliev, Nikolay (Federal State Budgetary Scientific Institution "Tomsk Cancer Research Institute") ;
  • Ananina, Olga (Federal State Budgetary Scientific Institution "Tomsk Cancer Research Institute") ;
  • Zharkova, Olga (Regional Clinical Oncology Center) ;
  • Rogovieva, Olga (Regional Clinical Oncology Center) ;
  • Verzhbitskaya, Natalia (Regional Clinical Oncology Center) ;
  • Didichuk, Ivan (Clinical Oncology Center) ;
  • Cheremisina, Olga (Federal State Budgetary Scientific Institution "Tomsk Cancer Research Institute") ;
  • Popova, Natalia (Federal State Budgetary Scientific Institution "Tomsk Cancer Research Institute") ;
  • Goldberg, Victor (Federal State Budgetary Scientific Institution "Tomsk Cancer Research Institute") ;
  • Cherdyntsev, Evgeny (National Research Tomsk Polytechnic University) ;
  • Choynzonov, Evgeny (Federal State Budgetary Scientific Institution "Tomsk Cancer Research Institute") ;
  • Cherdyntseva, Nadezda (Federal State Budgetary Scientific Institution "Tomsk Cancer Research Institute")
  • Published : 2015.02.25
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Incorporation of molecular analysis of the epidermal growth factor receptor (EGFR) gene into routine clinical practice has shown great promise to provide personalized therapy of the non-small cell lung cancer (NSCLC) in the developed world. However, the genetic testing of EGFR mutations has not yet become routine clinical practice in territories remote from the central regions of Russia. Therefore, we aimed to study the frequency of major types of activating mutations of the EGFR gene in NSCLC patients residing in West Siberia. Materials and Methods: We examined EGFR mutations in exons 19 and 21 in 147 NSCLC patients (excluding squamous cell lung carcinomas) by real time polymerase chain reaction. Results: EGFR mutations were detected in 28 of the 147 (19%) patients. There were 19 (13%) cases with mutations in exon 19 and 9 cases (6%) in exon 21. Mutations were more frequently observed in women (42%, p=0.000) than in men (1%). A significantly higher incidence of EGFR mutations was observed in bronchioloalveolar carcinomas (28%, p=0.019) and in adenocarcinomas (21%, p=0.024) than in large cell carcinomas, mixed adenocarcinomas, and NOS (4%). The EGFR mutation rate was much higher in never-smokers than in smokers: 38% vs. 3% (p=0.000). The frequency of EGFR mutations in the Kemerovo and Tomsk regions was 19%. Conclusions: The incorporation of molecular analysis of the EGFR gene into routine clinical practice will allow clinicians to provide personalised therapy, resulting in a significant increase in survival rates and improvement in life quality of advanced NSCLC patients.

Keywords

References

  1. Ahmed ZA, Moatter T, Siddiqui A, et al (2014). Distribution of EGFR mutations commonly observed in primary lung adenocarcinomas in Pakistan as predictors for targeted therapy. Asian Pac J Cancer Prev, 15, 7125-8. https://doi.org/10.7314/APJCP.2014.15.17.7125
  2. Aisner DL, Marshall CB (2012). Molecular pathology of nonsmall cell lung cancer: a practical guide. Am J Clin Pathol, 138, 332-46. https://doi.org/10.1309/AJCPFR12WJKCEEZZ
  3. Cherdyntseva NV, Gervas PA, Litvyakov NV, et al (2010). Agerelated function of tumor suppressor gene TP53:contribution to cancer risk and progression. Exp Oncol, 32, 205-8.
  4. Denisov EV, Litviakov NV, Zavyalova MV et al (2014). Intratumoral morphological heterogeneity of breast cancer: neoadjuvant chemotherapy efficiency and multidrug resistance gene expression. Sci Rep, 16, 4704-9.
  5. Gridelli C, De Marinis F, Di Maio M, et al (2011). Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: implications for clinical practice and open issues. Lung Cancer, 72, 3-8. https://doi.org/10.1016/j.lungcan.2010.12.009
  6. Imianitov EN (2008). Molecular diagnosis in oncology. Mol Biol, 42, 772-85.
  7. Jemal A, Siegel R, Xu J, et al (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300. https://doi.org/10.3322/caac.20073
  8. Kalinkin DE, Karpov AB, Takhauov RM et al. (2014). Mortality from cancer of the population living close to a large nuclear power plant. Vopr Onkol, 60, 41-6 (in Russian).
  9. Leidner RS, Fu P, Clifford B, et al (2009). Genetic abnormalities of the EGFR pathway in African American patients with non-small-cell lung cancer. J Clin Oncol, 33, 5620-6.
  10. Liam CK, Leow HR, How SH, et al (2014). Epidermal growth factor receptor mutations in non- small cell lung cancers in a multiethnic Malaysian patient population. Asian Pac J Cancer Prev, 15, 321-6. https://doi.org/10.7314/APJCP.2014.15.1.321
  11. Maemondo M, Inoue A, Kobayashi K, et al (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 25, 2380-8.
  12. Mun SA, Larin SA, Brailovskii VV, et al (2006). Ambient air benz[a]pyrene and cancer morbidity in Kemerovo. Gig Sanit, 4, 28-30 (in Russian).
  13. Ponomareva AA, Rykova EIu, Cherdyntseva NV et al. (2011). Molecular-genetic markers in lung cancer diagnostics. Mol Biol, 45, 203-17 ( in Russian).
  14. Yang ZM, Ding XP, Pen L, et al (2014). Analysis of CEA expression and EGFR mutation status in non-small cell lung cancers. Asian Pac J Cancer Prev, 15, 3451-5. https://doi.org/10.7314/APJCP.2014.15.8.3451

Cited by

  1. In silico insight into EGFR treatment in patients with lung carcinoma and T790M mutations vol.13, pp.5, 2017, https://doi.org/10.3892/etm.2017.4168